Results 191 to 200 of about 286,464 (363)

Infective Endocarditis: A Contemporary Review.

open access: yesMayo Clinic proceedings, 2020
Scott A Hubers   +3 more
semanticscholar   +1 more source

Endocarditis crónica

open access: yes, 1893
“En el estudio de las ciencias biológicas, como en el de las eminentemente prácticas, debe de relegarse á un lugar muy secundario y sospechoso todo cuanto no sea hijo legítimo de la más concienzuda experimentación (…) Cualquiera cuestión técnica expuesta en el seno de las doctas corporaciones, como cualquier hecho insólito de carácter epidémico que ...
openaire   +1 more source

Mapping the Burden and Risk Factors of Allergic Diseases and Asthma Among Aboriginal and Torres Strait Islander People: A Scoping Review

open access: yesClinical &Experimental Allergy, EarlyView.
Our study reveals Aboriginal and Torres Strait Islander people have a high allergy burden, with asthma the most prevalent; yet they remain under‐represented in research. ABSTRACT Allergic diseases and asthma are significant public health concerns in Australia and globally.
Desalegn Markos Shifti   +9 more
wiley   +1 more source

Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study.

open access: yesArchives of Internal Medicine, 2009
D. Murdoch   +22 more
semanticscholar   +1 more source

Cardiovascular Health in Women—Across the Lifespan

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Cardiovascular disease (CVD) remains the leading cause of mortality and morbidity among women worldwide. However, CVD continues to be perceived as a predominantly male issue. CVD in women therefore remains understudied, underrecognized and undertreated.
Jaya Chandrasekhar   +5 more
wiley   +1 more source

Impact of Prior Intravenous Immunoglobulin and Plasmapheresis on Eculizumab or Ravulizumab Treatment for Generalized Myasthenia Gravis: An Analysis of the MG SPOTLIGHT Registry

open access: yesClinical and Experimental Neuroimmunology, EarlyView.
ABSTRACT Objective The complement component 5 inhibitor therapies (C5ITs) eculizumab and ravulizumab are approved for the treatment of generalized myasthenia gravis (gMG). We evaluated the real‐world effectiveness and safety of eculizumab and ravulizumab in patients with gMG with or without prior intravenous immunoglobulin (IVIg) or plasma exchange ...
Akiyuki Uzawa   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy